AstroRx is under clinical development by Kadimastem and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AstroRx’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AstroRx overview

Stem cell therapy (AstroRx) is under development for the treatment of amyotrophic lateral sclerosis (ALS). The therapeutic candidate is administered through intrathecal route. It is based on Human Pluripotent Stem Cell-based (hPSC) solution technology. The therapy comprises of pluripotent stem cells that are artificially made from regular adult cells which have ability to differentiate to all the cell types of body. It was also under the development for the treatment for the treatment of multiple sclerosis and spinal cord injury.

Kadimastem overview

Kadimastem is a biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells and glia restricted progenitors derived from human pluripotent stem cells. The company’s medicine has potential applications for diabetes and neurodegenerative diseases such as ALS. Kadimastem has developed a groundbreaking process to differentiate the cells in the lab unlike other technologies which transplant immature precursor cells. Its regenerative medicine program is designed to allow large-scale production of encapsulated devices which is implanted in patients sensing blood glucose levels and secret insulin. The company also provides drug discovery and development services. Kadimastem is headquartered in Ness-Ziona, Israel.

For a complete picture of AstroRx’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.